A COMPANY PUT

@deegthinks

29.5K followers · usually 12.1K views a post

Views

29.5K

Likes

3.2K

Comments

99

Shares

456

SoundTikTok sound · original sound - slowedbyslip

Promoted product

Verve Therapeutics

Why it worked

The video taps into a significant ethical and scientific debate surrounding gene editing, presenting complex information in an accessible way. The hook of permanently altering human DNA and the implications for health and society are highly engaging.

Summary

This video discusses Verve Therapeutics' gene editing therapy, VERVE-102, which aims to permanently shut off the PCSK9 gene to lower cholesterol. The therapy has shown promising results in human trials, significantly reducing LDL cholesterol levels. The creator raises ethical questions about the technology's ability to rewrite human biology and questions who will control its application.

Structure

1Introduction to gene editing therapy for cholesterol
2Explanation of VERVE-102 and its mechanism
3Results from human trials showing effectiveness
4Discussion of ethical implications and future control

Original caption

Who gets to rewrite our genes? | source: https://www.nejm.org/doi/abs/10.1056/NEJMoa2601283 #dystopian #technology

More from @deegthinks

Product placement

Verve Therapeutics (ACTS - develops and tests gene editing therapies; its therapy VERVE-102 is the subject of the study; removing it would change the video's topic). NEJM.org (APPEARS - website where the study is published; removing it would not change the video's content). diegofill.com/paranoia (ACTS - a website/newsletter signup; removing it would change the video's call to action).

Call to action

Join the waitlist for my free newsletter through the bio.

On-screen text

A COMPANY PUT A GENE EDITOR IN AN IV BAG, RAN IT INTO AND PERMANENTLY SHUT OFF A GENE INSIDE OF THEIR OWN LIVING CELLS. A LAB DISH OR AN EMBRYO. GROWN ADULTS. THE NEJM.ORG THIS CONTENT IS COMPANY IS CALLED VERVE THERAPEUTICS. In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia Authors: Scott B. Vafai, M.D., Jörg Taubel, M.D., Thomas Ashdown, M.B., Ch.B., Riyaz S. Patel, M.B., B.S., M.D., Sadaf Diamondali, M.B., B.S., Jaimini Cegla, M.B., B.S., Ph.D., Handrean Soran, M.D., and Sekar Kathiresan, M.D. Author Info & Affiliations Published May 25, 2026 DOI: 10.1056/NEJMoa2601283 Copyright © 2026 Abstract BACKGROUND Persons carrying loss-of-function variants of proprotein convertase subtilisin-kexin type 9 (PCSK9) have reduced levels of low- density lipoprotein (LDL) cholesterol and fewer atherosclerotic cardiovascular disease events than persons without such variants. VERVE-102 is an investigational base-editing therapy designed to durably inactivate PCSK9 in the liver. A BASE EDITOR. IT GOES INTO CHANGES A SINGLE LETTER OF YOUR SHUT OFF A GENE CALLED P, S, K9. THAT'S THE ONE BAD CHOLESTEROL. HUMAN TRIAL THE EARLY DATA SHOWED LDL MORE THAN HALF. CONCLUSIONS One dose of VERVE-102 led to dose- dependent, substantial, and sustained reductions in PCSK9 and LDL cholesterol levels. (Funded by Verve Therapeutics; ClinicalTrials.gov number, NCT06164730.) LET THAT SINK IN AWAY. IN. FOR ALL OF HUMAN HISTORY, THE DNA WERE BORN WITH WAS THE SAME YOU DIED WITH. IT WAS THE ONE THING ABOUT FIXED. SO IS PERMANENTLY REWRITING SOMEONE'S BIOLOGY THE LINE? RIGHT NOW, IT'S CHOLESTEROL, AND THAT'S GENUINELY IT SAVES LIVES. BUT THE TECHNOLOGY DIFFERENCE BETWEEN FIXING AND CHANGING A TRAIT. IT JUST CHANGES WHATEVER LETTER YOU POINT AT WE BUILT THE PEN, BUT THE ONLY QUESTION LEFT IS WHO GETS TO WRITE? LINK IN BIO TO STAY UPDATED ON MORE DYSTOPIAN NEWSLETTER THROUGH THE BIO, BUT AS ALWAYS, LET ME KNOW FOLLOW ME.

Transcript

A company put a gene editor in an IV bag, ran it into and permanently shut off a gene inside of their own living cells. A lab dish or an embryo. Grown adults. The company is called Verve Therapeutics. In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia. Authors: Scott B. Vafai, M.D., Jörg Taubel, M.D., Thomas Ashdown, M.B., Ch.B., Riyaz S. Patel, M.B., B.S., M.D., Sadaf Diamondali, M.B., B.S., Jaimini Cegla, M.B., B.S., Ph.D., Handrean Soran, M.D., and Sekar Kathiresan, M.D. Author Info & Affiliations. Published May 25, 2026. DOI: 10.1056/NEJMoa2601283. Copyright © 2026. Abstract. BACKGROUND. Persons carrying loss-of-function variants of proprotein convertase subtilisin-kexin type 9 (PCSK9) have reduced levels of low-density lipoprotein (LDL) cholesterol and fewer atherosclerotic cardiovascular disease events than persons without such variants. VERVE-102 is an investigational base-editing therapy designed to durably inactivate PCSK9 in the liver. A BASE EDITOR. IT GOES INTO CHANGES A SINGLE LETTER OF YOUR SHUT OFF A GENE CALLED P, S, K9. THAT'S THE ONE BAD CHOLESTEROL. HUMAN TRIAL. THE EARLY DATA SHOWED LDL MORE THAN HALF. CONCLUSIONS. One dose of VERVE-102 led to dose-dependent, substantial, and sustained reductions in PCSK9 and LDL cholesterol levels. (Funded by Verve Therapeutics; ClinicalTrials.gov number, NCT06164730.). LET THAT SINK IN. AWAY. IN. FOR ALL OF HUMAN HISTORY, THE DNA WERE BORN WITH WAS THE SAME YOU DIED WITH. IT WAS THE ONE THING ABOUT FIXED. SO IS PERMANENTLY REWRITING SOMEONE'S BIOLOGY THE LINE? RIGHT NOW, IT'S CHOLESTEROL, AND THAT'S GENUINELY IT SAVES LIVES. BUT THE TECHNOLOGY DIFFERENCE BETWEEN FIXING AND CHANGING A TRAIT. IT JUST CHANGES WHATEVER LETTER YOU POINT AT. WE BUILT THE PEN, BUT THE ONLY QUESTION LEFT IS WHO GETS TO WRITE? LINK IN BIO TO STAY UPDATED ON MORE DYSTOPIAN NEWSLETTER THROUGH THE BIO, BUT AS ALWAYS, LET ME KNOW FOLLOW ME.